AACE/AME/ETA Thyroid Nodule Guidelines, Endocr Pract. 2010;16(Suppl 1 41 controlled clinical study. N Engl J Med. 1987;317:70-75. [EL 1] 121. La Rosa GL, Ippolito AM, Lupo L, et al. Cold thyroid nodule reduction with L-thyroxine can be predicted by initial nodule volume and cytological characteristics. J Clin Endocrinol Metab. 1996;81:4385-4387. [EL 2] 122. Papini E, Petrucci L, Guglielmi R, et al. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab. 1998;83:780783. [EL 1] 123. Wemeau JL, Caron P, Schvartz C, et al. Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by
the French Thyroid Research Group. J Clin Endocrinol Metab. 2002;87:4928-4934. [EL 1] 124. Hegedus L, Nygaard B, Hansen JM. Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified? J Clin Endocrinol Metab. 1999;84:756760. [EL 2] 125. Moalem J, Suh I, Duh QY. Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature. World J Surg. 2008;32:1301-1312. [EL 4] 126. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 1994;130: 350-356. [EL 1] 127. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: A meta-analysis. J Clin Endocrinol Metab. 1996;81:4278-4289. [EL 1] 128. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249-1252. [EL 2] 129. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10-year cohort study. Lancet. 2001;358:861-865. [EL 2] 130. La Rosa GL, Lupo L, Giuffrida D, Gullo D, Vigneri R, Belfiore A. Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid. Ann Intern Med. 1995;122:1-8. [EL 2] 131. Miccoli P, Minuto MN, Ugolini C, Pisano R, Fosso A, Berti P. Minimally invasive video-assisted thyroidectomy for benign thyroid disease: An evidence-based review. World J Surg. 2008;32:1333-1340. [EL 4—review] 132. Alvarado R, McMullen T, Sidhu SB, Delbridge LW, Sywak MS. Minimally invasive thyroid surgery for single nodules: an evidence-based review
of the lateral mini-incision technique. World J Surg. 2008;32:1341-1348. [EL 4—review] 133. Livraghi T, Paracchi A, Ferrari C, et al. Treatment of autonomous thyroid nodules with percutaneous ethanol injection: preliminary results: work in progress. Radiology. 1990;175:827-829. [EL 4] 134. Pacella CM, Bizzarri G, Guglielmi R, et al. Thyroid tissue: US-guided percutaneous interstitial laser ablation: a feasibility study. Radiology. 2000;217:673-677. [EL 3] 135. Verde G, Papini E, Pacella CM, et al. Ultrasound guided percutaneous ethanol injection in the treatment of cystic thyroid nodules. Clin Endocrinol (Oxf. 1994;41:719-724. [EL 1] 136. Guglielmi R, Pacella CM, Bianchini A, et al. Percutaneous ethanol injection treatment in benign thyroid lesions: role and efficacy. Thyroid. 2004;14:125-131. [EL 2] 137. Valcavi R, Frasoldati A. Ultrasound-guided percutaneous ethanol injection therapy in thyroid cystic nodules. Endocr Pract. 2004;10:269-275. [EL 3] 138. Kim JH, Lee HK, Lee JH, Ahn IM, Choi CG. Efficacy of sonographically guided percutaneous ethanol injection for treatment of thyroid cysts versus solid thyroid nodules. AJR Am J Roentgenol. 2003;180:1723-1726. [EL 3] 139. Zingrillo M, Torlontano M, Chiarella R, et al. Percutaneous ethanol injection may be a definitive treatment for symptomatic thyroid cystic nodules not treatable by surgery: Five-year follow-up study. Thyroid. 1999;9: 763-767. [EL 3] 140. Bennedbaek FN, Hegedus L. Treatment of recurrent thyroid cysts with ethanol: A randomized double-blind controlled trial. J Clin Endocrinol Metab. 2003;88:5773-5777. [EL 1] 141. Lippi F, Ferrari C, Manetti L, et al; the Multicenter Study Group. Treatment of solitary autonomous thyroid nodules by percutaneous ethanol injection: Results of an Italian multicenter study. J Clin Endocrinol Metab.
1996;81:32613264. [EL 3] 142. Livraghi T, Paracchi A, Ferrari C, Reschini E, Macchi RM, Bonifacino A. Treatment of autonomous thyroid nodules with percutaneous ethanol injection: 4-year experience. Radiology. 1994;190:529-533. [EL 3] 143. Zingrillo M, Collura D, Ghiggi MR, Nirchio V, Trischitta V. Treatment of large cold benign thyroid nodules not eligible for surgery with percutaneous ethanol injection. J Clin Endocrinol Metab. 1998;83:3905-3907. [EL 3] 144. Bennedbaek FN, Nielsen LK, Hegedus L. Effect of percutaneous ethanol injection therapy versus suppressive doses of L-thyroxine on benign solitary solid cold thyroid nodules: A randomized trial. J Clin Endocrinol Metab. 1998;83:830-835. [EL 1] 145. Kim YS, Rhim H, Tae K, Park DW, Kim ST. Radiofrequency ablation of benign cold thyroid nodules: Initial clinical experience. Thyroid. 2006;16:361-367. [EL 4] 146. Spiezia S, Garberoglio R, Milone F, et al. Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. Thyroid. 2009;19:219225. [EL 3] 147. Dossing H, Bennedbaek FN, Hegedus L. Effect of ultrasound-guided interstitial laser photocoagulation on benign solitary solid cold thyroid nodules: One versus three treatments. Thyroid. 2006;16:763-768. [EL 3] 148. Dossing H, Bennedbaek FN, Hegedus L. Effect of ultrasound-guided interstitial laser photocoagulation on benign solitary solid cold thyroid nodules: A randomised study. Eur J Endocrinol. 2005;152:341-345. [EL 2] 149. Papini E, Guglielmi R, Bizzarri G, et al. Treatment of benign cold thyroid nodules: A randomized clinical trial of percutaneous laser ablation versus levothyroxine therapy or follow-up. Thyroid. 2007;17:229-235. [EL 1] 150. Cakir B, Ugras NS, Gul K, Ersoy R, Korukluoglu B. Initial report of the results of percutaneous laser
ablation of benign cold thyroid nodules: Evaluation of histopathological changes after 2 years. Endocr Pathol. 2009;20:170-176. [EL 3] 151. Meier DA, Brill DR, Becker DV, et al; Society of Nuclear Medicine. Procedure guideline for therapy of thyroid disease with (131iodine. J Nucl Med. 2002;43:856-861. [EL 3—guidelines]
42 AACE/AME/ETA Thyroid Nodule Guidelines, Endocr Pract. 2010;16(Suppl 1 152. Nygaard B, Hegedus L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf. 1999;50:197-202. [EL 3] 153. Dietlein M, Dressler J, Grunwald F, et al; Deutsche Gesellschaft für Nuklearmedizin. Guideline for radioiodine therapy for benign thyroid diseases (version 4 [article in German]. Nuklearmedizin. 2007;46:220-223. [EL 4—guidelines] 154. Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med Mol Imaging. 2002;29(Suppl 2:S471-S478. [EL 3] 155. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular
and
cancer
mortality
after
radioiodine
treatment
for
hyperthyroidism [erratum in: J Clin Endocrinol Metab. 2007;92:4008]. J Clin Endocrinol Metab. 2007;92:2190-2196. [EL 2] 156. Ron E, Doody MM, Becker DV, et al; Cooperative Thyrotoxicosis Therapy Follow-up Study Group. Cancer mortality following treatment for adult hyperthyroidism. JAMA. 1998;280:347-355. [EL 3] 157. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: A 20 years’ retrospective study. Clin Endocrinol (Oxf. 2005;62:331-335. [EL 3] 158. Nygaard B,
Faber J, Veje A, Hegedis L, Hansen JM. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Thyroid. 1999;9:477481. [EL 3] 159. Nygaard B, Knudsen JH, Hegedus L, Scient AV, Hansen JE. Thyrotropin receptor antibodies and Graves’ disease, a side-effect of 131I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab. 1997;82:2926-2930. [EL 3] 160. Wallaschofski H, Muller D, Georgi P, Paschke R. Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment. Horm Metab Res. 2002;34:36-39. [EL 3] 161. Vos XG, Smit N, Endert E, Brosschot JF, Tijssen JG, Wiersinga WM. Age and stress as determinants of the severity of hyperthyroidism caused by Graves’ disease in newly diagnosed patients. Eur J Endocrinol. 2009;160:193199. [EL 3] 162. Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L. Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab. 2004;89:44394444. [EL 2] 163. Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007;334:514. [EL 1] 164. Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol (Oxf. 2007;66:757-764. [EL 4—review] 165. Hegedus L, Hansen BM, Knudsen N, Hansen JM. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. BMJ. 1988;297:661-662. [EL 3] 166. Nygaard B, Hegedus L, Gervil M, Hjalgrim H, SoeJensen P, Hansen JM. Radioiodine treatment of multinodular non-toxic goitre. BMJ. 1993;307:828-832. [EL 3] 167. Huysmans DA, Hermus AR, Corstens FH, Barentsz JO, Kloppenborg PW. Large, compressive goiters treated
with radioiodine. Ann Intern Med. 1994;121:757-762. [EL 3] 168. de Klerk JM, van Isselt JW, van Dijk A, et al. Iodine-131 therapy in sporadic nontoxic goiter. J Nucl Med. 1997;38: 372-376. [EL 3] 169. Fast S, Nielsen VE, Bonnema SJ, Hegedus L. Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. Eur J Endocrinol. 2009;160:517-528. [EL 4—review] 170. Wesche MF, Tiel-V Buul MM, Lips P, Smits NJ, Wiersinga WM. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab. 2001;86:9981005. [EL 1] 171. Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: Effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab. 1999;84:3636-3641. [EL 4] 172. Jarlov AE, Hegedus L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxf. 1995;43:325-329. [EL 3] 173. Nielsen VE, Bonnema SJ, Hegedus L. The effects of recombinant human thyrotropin, in normal subjects and patients with goitre. Clin Endocrinol (Oxf. 2004;61:655-663. [EL 4—review] 174. Nielsen VE, Bonnema SJ, Boel-Jorgensen H, Grupe P, Hegedus L. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med. 2006;166:1476-1482. [EL 1] 175. Silva MN, Rubio IG, Romao R, et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres.
Clin Endocrinol (Oxf. 2004;60:300308. [EL 3] 176. Nieuwlaat WA, Huysmans DA, van den Bosch HC, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab. 2003;88:3121-3129. [EL 3] 177. Barca MF, Gruppi C, Oliveira MT, et al. Cardiovascular assessment of hyperthyroid patients with multinodular goiter before and after radioiodine treatment preceded by stimulation with recombinant human TSH. Endocrine. 2007;32:175-181. [EL 3] 178. Nielsen VE, Bonnema SJ, Hegedus L. Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial. J Clin Endocrinol Metab. 2006;91:1317-1322. [EL 1] 179. Pena S, Arum S, Cross M, et al. 123I thyroid uptake and thyroid size at 24, 48, and 72 hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers. J Clin Endocrinol Metab. 2006;91:506510. [EL 3] 180. Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med. 2005;142:926-931. [EL 4] 181. Schlinkert RT, van Heerden JA, Goellner JR, et al. Factors that predict malignant thyroid lesions when fineneedle aspiration is “suspicious for follicular neoplasm.” Mayo Clin Proc. 1997;72:913-916. [EL 3] 182. Bartolazzi A, Orlandi F, Saggiorato E, et al; Italian Thyroid Cancer Study Group (ITCSG. Galectin-3expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 2008;9:543-549. [EL 2]
AACE/AME/ETA Thyroid Nodule Guidelines, Endocr Pract. 2010;16(Suppl 1 43 183. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:5175-5180. [EL 2] 184. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007;111:508-516. [EL 2] 185. Haymart MR, Greenblatt DY, Elson DF, Chen H. The role of intraoperative frozen section if suspicious for papillary thyroid cancer. Thyroid. 2008;18:419-423. [EL 3] 186. Cobin RH, Gharib H, Bergman DA, et al; Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: Management of thyroid carcinoma [erratum in: Endocr Pract. 2008;14:802-803]. Endocr Pract. 2001;7:202-220. [EL 4—guidelines] 187. Cooper DS, Doherty GM, Haugen BR, et al; American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142. [EL 4—guidelines] 188. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium [erratum in: Eur J Endocrinol. 2006;155:385]. Eur J Endocrinol. 2006;154:787-803. [EL 4—consensus] 189. National Comprehensive Cancer Network. NCCN categories of evidence and consensus [cited March 2009]. Available
at:
http://www.nccn.org/professionals/physician_gls/categories_of_consensus.asp. [EL 4—guidelines] 190. Baloch ZW, Barroeta JE, Walsh J, et al. Utility of thyroglobulin
measurement in fine-needle aspiration biopsy specimens of lymph nodes in the diagnosis of recurrent thyroid carcinoma. Cytojournal. 2008;5:1. [EL 4] 191. Kim E, Park JS, Son KR, Kim JH, Jeon SJ, Na DG. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: Comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid. 2008;18:411-418. [EL 3] 192. Freudenberg LS, Antoch G, Jentzen W, et al. Value of (124I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol. 2004;14:2092-2098. [EL 3] 193. Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007;92(Suppl 8:S1-S47. [EL 4—guidelines] 194. Kung AW, Chau MT, Lao TT, Tam SC, Low LC. The effect of pregnancy on thyroid nodule formation. J Clin Endocrinol Metab. 2002;87:1010-1014. [EL 2] 195. Rosen IB, Korman M, Walfish PG. Thyroid nodular disease in pregnancy: Current diagnosis and management. Clin Obstet Gynecol. 1997;40:81-89. [EL 4] 196. Marley EF, Oertel YC. Fine-needle aspiration of thyroid lesions in 57 pregnant and postpartum women. Diagn Cytopathol. 1997;16:122-125. [EL 3] 197. Moosa M, Mazzaferri EL. Outcome of differentiated thyroid cancer diagnosed in pregnant women. J Clin Endocrinol Metab. 1997;82:2862-2866. [EL 3] 198. Rallison ML, Dobyns BM, Keating FR Jr, Rall JE, Tyler FH. Thyroid nodularity in children. JAMA. 1975;233:10691072. [EL 4] 199. Hung W. Nodular thyroid disease and thyroid carcinoma. Pediatr Ann. 1992;21:50-57. [EL 4—review] 200. Niedziela M. Pathogenesis, diagnosis and management of thyroid nodules in children. Endocr Relat Cancer. 2006;13:427-
453. [EL 4—review] 201. Raab SS, Silverman JF, Elsheikh TM, Thomas PA, Wakely PE. Pediatric thyroid nodules: Disease demographics and clinical management as determined by fine needle aspiration biopsy. Pediatrics. 1995;95:46-49. [EL 3] 202. Amrikachi M, Ponder TB, Wheeler TM, Smith D, Ramzy I. Thyroid fine-needle aspiration biopsy in children and adolescents: experience with 218 aspirates. Diagn Cytopathol. 2005;32:189-192. [EL 3] 203. Chang SH, Joo M, Kim H. Fine needle aspiration biopsy of thyroid nodules in children and adolescents. J Korean Med Sci. 2006;21:469-473. [EL 3] 204. Belfiore A, La Rosa GL, Padova G, Sava L, Ippolito O, Vigneri R. The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine-deficient area. Cancer. 1987;60:3096-3102. [EL 3] 205. Canadian Pediatric Thyroid Nodule (CaPTN Study Group. The Canadian Pediatric Thyroid Nodule Study: An evaluation of current management practices. J Pediatr Surg. 2008;43:826-830. [EL 4] 206. Drozd VM, Lushchik ML, Polyanskaya ON, et al. The usual ultrasonographic features of thyroid cancer are less frequent in small tumors that develop after a long latent period after the Chernobyl radiation release accident. Thyroid. 2009;19:725-734. [EL 2] 207. Feinmesser R, Lubin E, Segal K, Noyek A. Carcinoma of the thyroid in children: A review. J Pediatr Endocrinol Metab. 1997;10:561-568. [EL 4—review] 208. Alessandri AJ, Goddard KJ, Blair GK, Fryer CJ, Schultz KR. Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. Med Pediatr Oncol. 2000;35:41-46. [EL 3] 209. Niedziela M, Breborowicz D, Trejster E, Korman E. Hot nodules in children and adolescents in western Poland from 1996 to 2000: Clinical analysis of 31 patients. J Pediatr Endocrinol Metab. 2002;15:823-
830. [EL 3] 210. Haynes RB, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC. Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J Am Med Inform Assoc. 1994;1:447-458. [EL 4] 211. Hunt DL, McKibbon KA. Locating and appraising systematic reviews. Ann Intern Med. 1997;126:532-538. [EL 4] 212. Mechanick JI, Bergman DA, Braithwaite SS, Palumbo PJ; American Association of Clinical Endocrinologists Ad Hoc Task Force for Standardized Production of Clinical Practice Guidelines. American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines [erratum in: Endocr Pract. 2008;14:802-803]. Endocr Pract. 2004;10:353-361. [EL 4—guidelines] 213. Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract. 2008;14(Suppl 1:1-83. [EL 4—guidelines] 214. Gharib H, Papini E, Paschke R. Thyroid nodules: A review of current guidelines, practices, and prospects. Eur J Endocrinol. 2008;159:493-505. [EL 4—review]
因篇幅问题不能全部显示，请点此查看更多更全内容